Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study. (PubMed, Endocr J) - Oct 1, 2026 - P=N/A | "In this multicenter retrospective single-arm observational study, HbA1c and BMI decreased over 24 weeks after low-dose tirzepatide initiation in Japanese people with T2D. These findings suggest that low-dose tirzepatide may be a useful treatment option in selected patients in routine clinical practice, although causal inference is limited by the observational design and lack of a control group.Trial Registration: National University Hospital Medical Information Network (UMIN Clinical Trial Registry, UMIN000053671; approval date: March 1, 2024)."
Journal • Observational data • Real-world evidence • Retrospective data • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
; Daisuke Takarabe; Hirotaka Watada; Jo Nagakura; Katsumi Aso; Katsutoshi Komatsu; Ken Sato; Marie Kanzaki; Naoaki Ito; Naoko Enosawa; Nozomu Yamasaki; Shuko Nojiri; Takashi Nomiyama; Tatsuya Iwamoto; Wataru Urasaki
|